Risk factors

Breast Cancer Risk Reduction and Early Detection

Volumn , Issue , 2010, Pages 3-22

  Newcomb, Polly A ^a,b   Wernli, Karen J ^a  

^a Fred Hutchinson Cancer Research Center   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Breast cancer epidemiology; Incidence; Risk factors

Indexed keywords

EID: 84885696293     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-0-387-87583-5_1     Document Type: Chapter

References (164)

1. Ries L A G, Melbert D, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2004, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/ 1975-2004/, based on November 2006 SEER data submission, posted to the SEER web site, 2007.
2. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin. Mar-Apr. 2008;58(2):71-96.
3. White E. Projected changes in breast cancer incidence due to the trend toward delayed childbearing. Am J Public Health. Apr. 1987;77(4):495-497.
4. Lantz PM, Remington PL, Newcomb PA. Mammography screening and increased incidence of breast cancer in Wisconsin. J Natl Cancer Inst. Nov. 6, 1991;83(21):1540-1546.
5. White E, Lee CY, Kristal AR. Evaluation of the increase in breast cancer incidence in relation to mammography use. J Natl Cancer Inst. Oct. 3, 1990;82(19):1546-1552.
6. Kessler LG, Feuer EJ, Brown ML. Projections of the breast cancer burden to U. S. women: 1990-2000. Prev Med. Jan 1991;20(1):170-182.
7. Berry DA, Cronin KA, Plevritis SK, et al. Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med. Oct. 27, 2005;353(17):1884-1892.
8. Heck KE, Pamuk ER. Explaining the relation between education and postmenopausal breast cancer. Am J Epidemiol. Feb. 15, 1997;145(4):366-372.
9. Krieger N, Van Den Eeden SK, Zava D, Okamoto A. Race/ethnicity, social class, and prevalence of breast cancer prognostic biomarkers: a study of white, black, and Asian women in the San Francisco bay area. Ethn Dis. 1997;7(2):137-149.
10. Krieger N. Social class and the black/white crossover in the age-specific incidence of breast cancer: a study linking census-derived data to population-based registry records. Am J Epidemiol. May 1990;131(5):804-814.
11. Laden F, Spiegelman D, Neas LM, et al. Geographic variation in breast cancer incidence rates in a cohort of U. S. women. J Natl Cancer Inst. Sep. 17, 1997;89(18):1373-1378.
12. CollaborativeGroup. Familial breast cancer: collaborative reanalysis of individual data from 52 epidemiological studies including 58, 209 women with breast cancer and 101, 986 women without the disease. Lancet. Oct. 27, 2001;358(9291):1389-1399.
13. Ellisen LW, Haber DA. Hereditary breast cancer. Annu Rev Med. 1998;49:425-436.
14. Newman B, Austin MA, Lee M, King MC. Inheritance of human breast cancer: evidence for autosomal dominant transmission in high-risk families. Proc Natl Acad Sci U S A. May 1988;85(9):3044-3048.
15. Go RC, King MC, Bailey-Wilson J, Elston RC, Lynch HT. Genetic epidemiology of breast cancer and associated cancers in high-risk families. I. Segregation analysis. J Natl Cancer Inst. Sep. 1983;71(3):455-461.
16. Narod SA, Feunteun J, Lynch HT, et al. Familial breast-ovarian cancer locus on chromosome 17q12-q23. Lancet. Jul. 13, 1991;338(8759):82-83.
17. Hall JM, Lee MK, Newman B, et al. Linkage of early-onset familial breast cancer to chromosome 17q21. Science. Dec. 21, 1990;250(4988):1684-1689.
18. Easton D, Ford D, Peto J. Inherited susceptibility to breast cancer. Cancer Surv. 1993;18:95-113.
19. Antoniou A, Pharoah PD, Narod S, et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet. May 2003;72(5):1117-1130.
20. Abbott DW, Thompson ME, Robinson-Benion C, Tomlinson G, Jensen RA, Holt JT. BRCA1 expression restores radiation resistance in BRCA1-defective cancer cells through enhancement of transcription-coupled DNA repair. J Biol Chem. Jun. 25 1999;274(26):18808-18812.
21. Gowen LC, Avrutskaya AV, Latour AM, Koller BH, Leadon SA. BRCA1 required for transcription-coupled repair of oxidative DNA damage. Science. Aug. 14, 1998;281(5379):1009-1012.
22. Scully R, Chen J, Plug A, et al. Association of BRCA1 with Rad51 in mitotic and meiotic cells. Cell. Jan 24, 1997;88(2):265-275.
23. Ford D, Easton DF, Stratton M, et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet. Mar. 1998;62(3):676-689.
24. Sellers TA, Mink PJ, Cerhan JR, et al. The role of hormone replacement therapy in the risk for breast cancer and total mortality in women with a family history of breast cancer. Ann Intern Med. 1997;127(11):973-980.
25. Li FP, Fraumeni JF Jr. Soft-tissue sarcomas, breast cancer, and other neoplasms. A familial syndrome? Ann Intern Med. Oct. 1969;71(4):747-752.
26. Varley JM, McGown G, Thorncroft M, et al. Are there low-penetrance TP53 Alleles? evidence from childhood adrenocortical tumors. Am J Hum Genet. Oct. 1999;65(4):995-1006.
27. Swift M, Morrell D, Massey RB, Chase CL. Incidence of cancer in 161 families affected by ataxiatelangiectasia. N Engl J Med. Dec. 26, 1991;325(26):1831-1836.
28. Janin N, Andrieu N, Ossian K, et al. Breast cancer risk in ataxia telangiectasia (AT) heterozygotes: haplotype study in French AT families. Br J Cancer. Jun. 1999;80(7):1042-1045.
29. Nelen MR, Padberg GW, Peeters EA, et al. Localization of the gene for Cowden disease to chromosome 10q22. Nat Genet. May 1996;13(1):114-116.
30. Schrager CA, Schneider D, Gruener AC, Tsou HC, Peacocke M. Clinical and pathological features of breast disease in Cowden's syndrome: an underrecognized syndrome with an increased risk of breast cancer. Hum Pathol. Jan 1998;29(1):47-53.
31. Peto J, Houlston RS. Genetics and the common cancers. Eur J Cancer. Oct. 2001;37(Suppl 8):S88-S96.
32. Kelsey JL, Gammon MD, John EM. Reproductive factors and breast cancer. Epidemiol Rev. 1993;15(1):36-47.
33. Nichols HB, Trentham-Dietz A, Hampton JM, et al. From menarche to menopause: trends among US women born from 1912 to 1969. Am J Epidemiol. Nov. 15, 2006;164(10):1003-1011.
34. Chie W-C, Hsieh C-C, Newcomb PA, et al. Age at any full-term pregnancy and breast cancer risk. Am J Epidemiol. 2000;151(7):715-722.
35. Bruzzi P, Negri E, La Vecchia C, et al. Short term increase in risk of breast cancer after full term pregnancy. Bmj. Oct. 29, 1988;297(6656):1096-1098.
36. Hsieh CC, Trichopoulos D, Katsouyanni K, Yuasa S. Age at menarche, age at menopause, height and obesity as risk factors for breast cancer: associations and interactions in an international case-control study. Int J Cancer. Nov. 15, 1990;46(5):796-800.
37. CollaborativeGroup. Breast cancer and breastfeeding: collaborative reanalysis of individual data from 47 epidemiological studies in 30 countries, including 50302 women with breast cancer and 96973 women without the disease. Lancet. Jul. 20, 2002;360(9328):187-195.
38. Trichopoulos D, Hsieh CC, MacMahon B, et al. Age at any birth and breast cancer risk. Int J Cancer. Jun. 15, 1983;31(6):701-704.
39. Russo J, Russo IH. Toward a physiological approach to breast cancer prevention. Cancer Epidemiol Biomarkers Prev. Jun. 1994;3(4):353-364.
40. Lipworth L, Bailey LR, Trichopoulos D. History of breast-feeding in relation to breast cancer risk: a review of the epidemiologic literature. J Natl Cancer Inst. Feb. 16, 2000;92(4):302-312.
41. Romieu I, Hernandez-Avila M, Lazcano E, Lopez L, Romero-Jaime R. Breast cancer and lactation history in Mexican women. Am J Epidemiol. Mar. 15, 1996;143(6):543-552.
42. Newcomb PA, Storer BE, Longnecker MP, et al. Lactation and a reduced risk of premenopausal breast cancer. N Engl J Med. Jan 13, 1994;330(2):81-87.
43. Trichopoulos D. Hypothesis: does breast cancer originate in utero? Lancet. Apr. 21, 1990;335(8695):939-940.
44. Trentham-Dietz A, Newcomb PA, Storer BE, Longnecker MP, Mittendorf R. Multiple births and risk of breast cancer. Int J Cancer. 1995;62:162-164.
45. Barba M, McCann SE, Nie J, et al. Perinatal exposures and breast cancer risk in the Western New York Exposures and Breast Cancer (WEB) Study. Cancer Causes Control. May 2006;17(4):395-401.
46. Titus-Ernstoff L, Newcomb PA, Egan KM, et al. Left-handedness in relation to breast cancer risk in postmenopausal women. Epidemiology. Mar. 2000;11(2):181-184.
47. Hodgson ME, Newman B, Millikan RC. Birthweight, parental age, birth order and breast cancer risk in African-American and white women: a population-based case-control study. Breast Cancer Res. 2004;6(6):R656-R667.
48. Xue F, Michels KB. Intrauterine factors and risk of breast cancer: a systematic review and meta-analysis of current evidence. Lancet Oncol. Dec. 2007;8(12):1088-1100.
49. Nichols HB, Trentham-Dietz A, Sprague BL, Hampton JM, Titus-Ernstoff L, Newcomb PA. Effects of birth order and maternal age on breast cancer risk: modification by whether women had been breast-fed. Epidemiology. May 2008;19(3):417-423.
50. Bernstein L. Epidemiology of endocrine-related risk factors for breast cancer. J Mammary Gland Biol Neoplasia. Jan 2002;7(1):3-15.
51. CollaborativeGroup. Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53 297 women with breast cancer and 100 239 women without breast cancer from 54 epidemiological studies. Collaborative Group on Hormonal Factors in Breast Cancer. Lancet. Jun. 22, 1996;347(9017):1713-1727.
52. IARC. Combined Estrogen-Progestogen Contraceptives and Combined Estrogen-Progestogen Menopausal Therapy. Lyon, France: WHO/IARC; 2007.
53. Newcomb PA, Longnecker MP, Storer BE, et al. Recent oral contraceptive use and risk of breast cancer (United States). Cancer Causes Control. Sep. 1996;7(5):525-532.
54. CollaborativeGroup. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52, 705 women with breast cancer and 108, 411 women without breast cancer. Collaborative Group on Hormonal Factors in Breast Cancer. Lancet. 1997;350(9084):1047-1059.
55. Li CI, Malone KE, Porter PL, et al. Relationship between long durations and different regimens of hormone therapy and risk of breast cancer. JAMA. Jun. 25, 2003;289(24):3254-3263.
56. Chen CL, Weiss NS, Newcomb P, Barlow W, White E. Hormone replacement therapy in relation to breast cancer. JAMA. Feb. 13, 2002;287(6):734-741.
57. Ross RK, Paganini-Hill A, Wan PC, Pike MC. Effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin. J Natl Cancer Inst. 2000;92(4):328-332.
58. Porch JV, Lee IM, Cook NR, Rexrode KM, Buring JE. Estrogen-progestin replacement therapy and breast cancer risk: the Women's Health Study (United States). Cancer Causes Control. 2002;13:847-854.
59. Weiss LK, Burkman RT, Cushing-Haugen KL, et al. Hormone replacement therapy regimens and breast cancer risk (1). Obstet Gynecol. Dec. 2002;100(6):1148-1158.
60. Olsson HL, Ingvar C, Bladstrom A. Hormone replacement therapy containing progestins and given continuously increases breast carcinoma risk in Sweden. Cancer. Mar. 15, 2003;97(6):1387-1392.
61. Newcomb PA, Longnecker MP, Storer BE, et al. Long-term hormone replacement therapy and risk of breast cancer in postmenopausal women. Am J Epidemiol. Oct. 15, 1995;142(8):788-795.
62. Beral V. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet. Aug. 9, 2003;362(9382):419-427.
63. Anderson GL, Limacher M, Assaf AR, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA. Apr. 14, 2004;291(14):1701-1712.
64. Grady D. Postmenopausal hormones-therapy for symptoms only. N Engl J Med. May 8, 2003;348(19):1835-1837.
65. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA. 2002;288(3):321-333.
66. Buist DS, Newton KM, Miglioretti DL, et al. Hormone therapy prescribing patterns in the United States. Obstet Gynecol. Nov. 2004;104(5 Pt 1):1042-1050.
67. Hersh AL, Stefanick ML, Stafford RS. National use of postmenopausal hormone therapy: annual trends and response to recent evidence. JAMA. Jan 7, 2004;291(1):47-53.
68. Ravdin PM, Cronin KA, Howlader N, et al. The decrease in breast-cancer incidence in 2003 in the United States. N Engl J Med. Apr. 19, 2007;356(16):1670-1674.
69. Jordan VC. Antiestrogenic action of raloxifene and tamoxifen: today and tomorrow. J Natl Cancer Inst. 1998;90(13):967-971.
70. Gail MH, Brinton LA, Byar DP, et al. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst. 1989;81(24):1879-1886.
71. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. [see comments]. J Natl Cancer Inst. 1998;90(18):1371-1388.
72. Ettinger B, Black DM, Mitlak BH, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA. Aug. 18, 1999;282(7):637-645.
73. Cummings SR, Eckert S, Krueger KA, et al. The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. JAMA. 1999;281(23):2189-2197.
74. Cauley JA, Norton L, Lippman ME, et al. Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation. Breast Cancer Res Treat. Jan 2001;65(2):125-134.
75. Vogel VG, Costantino JP, Wickerham DL, et al. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA. Jun. 21, 2006;295(23):2727-2741.
76. Baum M, Buzdar A. The current status of aromatase inhibitors in the management of breast cancer. Surg Clin North Am. Aug. 2003;83(4):973-994.
77. Cuzick J. Aromatase inhibitors in prevention-data from the ATAC (arimidex, tamoxifen alone or in combination) trial and the design of IBIS-II (the second International Breast Cancer Intervention Study). Recent Results Cancer Res. 2003;163:96-103 discussion 264-106.
78. Lewison EF, Lyons JG Jr. Relationship between benign breast disease and cancer. AMA Arch Surg. Jan 1953;66(1):94-114.
79. Hartmann LC, Sellers TA, Frost MH, et al. Benign breast disease and the risk of breast cancer. N Engl J Med. Jul. 21, 2005;353(3):229-237.
80. Santen RJ, Mansel R. Benign breast disorders. N Engl J Med. Jul. 21, 2005;353(3):275-285.
81. McDivitt RW, Stevens JA, Lee NC, Wingo PA, Rubin GL, Gersell D. Histologic types of benign breast disease and the risk for breast cancer. The Cancer and Steroid Hormone Study Group. Cancer. Mar. 15 1992;69(6):1408-1414.
82. London SJ, Connolly JL, Schnitt SJ, Colditz GA. A prospective study of benign breast disease and the risk of breast cancer. JAMA. Feb. 19, 1992;267(7):941-944.
83. Worsham MJ, Abrams J, Raju U, et al. Breast cancer incidence in a cohort of women with benign breast disease from a multiethnic, primary health care population. Breast J. Mar-Apr. 2007;13(2):115-121.
84. Rohan TE, Negassa A, Chlebowski RT, et al. Estrogen plus progestin and risk of benign proliferative breast disease. Cancer Epidemiol Biomarkers Prev. Sep. 2008;17(9):2337-2343.
85. Marshall LM, Hunter DJ, Connolly JL, et al. Risk of breast cancer associated with atypical hyperplasia of lobular and ductal types. Cancer Epidemiol Biomarkers Prev. May 1997;6(5):297-301.
86. Degnim AC, Visscher DW, Berman HK, et al. Stratification of breast cancer risk in women with atypia: a Mayo cohort study. J Clin Oncol. Jul. 1, 2007;25(19):2671-2677.
87. Rohan TE, Hartwick W, Miller AB, Kandel RA. Immunohistochemical detection of c-erbB-2 and p53 in benign breast disease and breast cancer risk. J Natl Cancer Inst. Sep. 2, 1998;90(17):1262-1269.
88. Van Gils CH, Hendriks JH, Otten JD, Holland R, Verbeek AL. Parity and mammographic breast density in relation to breast cancer risk: indication of interaction. Eur J Cancer Prev. Apr. 2000;9(2):105-111.
89. Boyd NF, Lockwood GA, Byng JW, Tritchler DL, Yaffe MJ. Mammographic densities and breast cancer risk. Cancer Epidemiol Biomarkers Prev. Dec. 1998;7(12):1133-1144.
90. Boyd NF, Rommens JM, Vogt K, et al. Mammographic breast density as an intermediate phenotype for breast cancer. Lancet Oncol. Oct. 2005;6(10):798-808.
91. Ursin G, Ma H, Wu AH, et al. Mammographic density and breast cancer in three ethnic groups. Cancer Epidemiol Biomarkers Prev. Apr. 2003;12(4):332-338.
92. Boyd NF, Guo H, Martin LJ, et al. Mammographic density and the risk and detection of breast cancer. N Engl J Med. Jan 18 2007;356(3):227-236.
93. McTiernan A, Martin CF, Peck JD, et al. Estrogen-plus-progestin use and mammographic density in postmenopausal women: women's health initiative randomized trial. J Natl Cancer Inst. Sep. 21 2005;97(18):1366-1376.
94. Vachon CM, Brandt KR, Ghosh K, et al. Mammographic breast density as a general marker of breast cancer risk. Cancer Epidemiol Biomarkers Prev. Jan 2007;16(1):43-49.
95. Barlow WE, White E, Ballard-Barbash R, et al. Prospective breast cancer risk prediction model for women undergoing screening mammography. J Natl Cancer Inst. Sep. 6, 2006;98(17):1204-1214.
96. IARC. IARC Handbooks of Cancer Prevention: Weight Control and Physical Activity. Vol 6. Lyon, France: IARC; 2002.
97. Van Den Brandt PA. Pooled analysis of prospective cohort studies on height, weight, and breast cancer risk. Am J Epidemiol. 2000;152(6):514-527.
98. Lahmann PH, Hoffmann K, Allen N, et al. Body size and breast cancer risk: findings from the European Prospective Investigation into Cancer and Nutrition (EPIC). Int J Cancer. Sep. 20, 2004;111(5):762-771.
99. Trentham-Dietz A, Newcomb PA, Egan KM, et al. Weight change and risk of postmenopausal breast cancer (United States). Cancer Causes Control. Jul. 2000;11(6):533-542.
100. Trentham-Dietz A, Newcomb PA, Storer BE, et al. Body size and risk of breast cancer. Am J Epidemiol. Jun. 1, 1997;145(11):1011-1019.
101. Feigelson HS, Jonas CR, Teras LR, Thun MJ, Calle EE. Weight gain, body mass index, hormone replacement therapy, and postmenopausal breast cancer in a large prospective study. Cancer Epidemiol Biomarkers Prev. Feb. 2004;13(2):220-224.
102. Baer HJ, Colditz GA, Rosner B, et al. Body fatness during childhood and adolescence and incidence of breast cancer in premenopausal women: a prospective cohort study. Breast Cancer Res. 2005;7(3):R314-R325.
103. Freedman DS, Khan LK, Serdula MK, Dietz WH, Srinivasan SR, Berenson GS. The relation of menarcheal age to obesity in childhood and adulthood: the Bogalusa heart study. BMC Pediatr. Apr. 30, 2003;3:3.
104. Friedenreich CM, Orenstein MR. Physical activity and cancer prevention: etiologic evidence and biological mechanisms. J Nutr. Nov. 2002;132(11 Suppl):3456S-3464S.
105. Monninkhof EM, Elias SG, Vlems FA, et al. Physical activity and breast cancer: a systematic review. Epidemiology. Jan 2007;18(1):137-157.
106. Mittendorf R, Longnecker MP, Newcomb PA, et al. Strenuous physical activity in young adulthood and risk of breast cancer (United States). Cancer Causes Control. Jul. 1995;6(4):347-353.
107. Sprague BL, Trentham-Dietz A, Newcomb PA, Titus-Ernstoff L, Hampton JM, Egan KM. Lifetime recreational and occupational physical activity and risk of in situ and invasive breast cancer. Cancer Epidemiol Biomarkers Prev. Feb. 2007;16(2):236-243.
108. Nkondjock A, Robidoux A, Paredes Y, Narod SA, Ghadirian P. Diet, lifestyle and BRCA-related breast cancer risk among French-Canadians. Breast Cancer Res Treat. Aug. 2006;98(3):285-294.
109. IARC. IARC Handbook of Cancer Prevention, vol 6:Weight Control and Physical Activity. Lyon, France: IARC; 2002.
110. Ballard-Barbash R, Blair A, Blair SN, et al. Physical activity across the cancer continuum: report of a workshop: review of existing knowledge and innovative designs for future research. Cancer. Sep. 1, 2002;95(5):1134-1143.
111. Smith-Warner SA, Spiegelman D, Yaun SS, et al. Alcohol and breast cancer in women: a pooled analysis of cohort studies. JAMA. Feb. 18, 1998;279(7):535-540.
112. CollaborativeGroup. Alcohol, tobacco and breast cancer-collaborative reanalysis of individual data from 53 epidemiological studies, including 58, 515 women with breast cancer and 95, 067 women without the disease. Br J Cancer. Nov. 18, 2002;87(11):1234-1245.
113. Zhang SM, Lee IM, Manson JE, Cook NR, Willett WC, Buring JE. Alcohol consumption and breast cancer risk in the Women's Health Study. Am J Epidemiol. Mar. 15, 2007;165(6):667-676.
114. WCRF/AICR. Food, Nutrition, Physical Activity, and the Prevention of Cancer: a Global Perspective. Washington DC: AICR; 2007.
115. Terry MB, Zhang FF, Kabat G, et al. Lifetime alcohol intake and breast cancer risk. Ann Epidemiol. Mar. 2006;16(3):230-240.
116. Singletary K, Gapstur S. Alcohol and breast cancer: review of epidemiologic and experimental evidence and potential mechanisms. JAMA. Nov, 7 2001;286(17):2143-2151.
117. Boffetta P, Hashibe M. Alcohol and cancer. Lancer Oncol. 2006;7:149-156.
118. WCRF/AICR. Expert Report. Food, Nutrition, Physical Activity, and the Prevention of Cancer: A Global Perspective. Washington DC: AICR; 2007.
119. Smith-Warner SA, Spiegelman D, Adami HO, et al. Types of dietary fat and breast cancer: a pooled analysis of cohort studies. Int J Cancer. Jun. 1, 2001;92(5):767-774.
120. Prentice RL, Caan B, Chlebowski RT, et al. Low-fat dietary pattern and risk of invasive breast cancer: the Women's Health Initiative randomized controlled dietary modification trial. JAMA. Feb. 8 2006;295(6):629-642.
121. Smith-Warner SA, Spiegelman D, Yaun SS, et al. Intake of fruits and vegetables and risk of breast cancer: a pooled analysis of cohort studies. JAMA. Feb. 14, 2001;285(6):769-776.
122. Michels KB, Mohllajee AP, Roset-Bahmanyar E, Beehler GP, Moysich KB. Diet and breast cancer: a review of the prospective observational studies. Cancer. Jun. 15, 2007;109(12 Suppl):2712-2749.
123. Freedman LS, Potischman N, Kipnis V, et al. A comparison of two dietary instruments for evaluating the fatbreast cancer relationship. Int J Epidemiol. Aug. 2006;35(4):1011-1021.
124. Terry MB, Gammon MD, Zhang FF, et al. Association of frequency and duration of aspirin use and hormone receptor status with breast cancer risk. J Am Med Assoc. May 26, 2004;291(20):2433-2440.
125. Pocobelli G, Newcomb PA, Trentham-Dietz A, Titus-Ernstoff L, Hampton JM, Egan KM. Statin use and risk of breast cancer. Cancer. Jan 1, 2008;112(1):27-33.
126. Wernli KJ, Hampton JM, Trentham-Dietz A, Newcomb PA. Antidepressant medication use and breast cancer risk. Pharmacoepidemiol 2009;18(4):284-290.
127. Terry PD, Rohan TE. Cigarette smoking and the risk of breast cancer in women: a review of the literature. Cancer Epidemiol Biomarkers Prev. Oct. 2002;11(10 Pt 1):953-971.
128. Cui Y, Miller AB, Rohan TE. Cigarette smoking and breast cancer risk: update of a prospective cohort study. Breast Cancer Res Treat. Dec. 2006;100(3):293-299.
129. Pirie K, Beral V, Peto R, Roddam A, Reeves G, Green J. Passive smoking and breast cancer in never smokers: prospective study and meta-analysis. Int J Epidemiol. Oct. 2008;37(5):1069-1079.
130. Terry PD, Goodman M. Is the association between cigarette smoking and breast cancer modified by genotype? A review of epidemiologic studies and meta-analysis. Cancer Epidemiol Biomarkers Prev. Apr. 2006;15(4):602-611.
131. Brody JG, Moysich KB, Humblet O, Attfield KR, Beehler GP, Rudel RA. Environmental pollutants and breast cancer: epidemiologic studies. Cancer. Jun. 15 2007;109(12 Suppl):2667-2711.
132. Wolff MS, Toniolo PG. Environmental organochlorine exposure as a potential etiologic factor in breast cancer. Environ Health Perspect. Oct. 1995;103(Suppl 7):141-145.
133. Calle EE, Frumkin H, Henley SJ, Savitz DA, Thun MJ. Organochlorines and breast cancer risk. CA Cancer J Clin. Sep-Oct. 2002;52(5):301-309.
134. Cohn BA, Wolff MS, Cirillo PM, Sholtz RI. DDT and breast cancer in young women: new data on the significance of age at exposure. Environ Health Perspect. Oct. 2007;115(10):1406-1414.
135. Romieu I, Hernandez-Avila M, Lazcano-Ponce E, Weber JP, Dewailly E. Breast cancer, lactation history, and serum organochlorines. Am J Epidemiol. Aug. 15, 2000;152(4):363-370.
136. Laden F, Ishibe N, Hankinson SE, et al. Polychlorinated biphenyls, cytochrome P450 1A1, and breast cancer risk in the Nurses Health Study. Cancer Epidemiol Biomarkers Prev. Dec. 2002;11(12):1560-1565.
137. Moysich KB, Shields PG, Freudenheim JL, et al. Polychlorinated biphenyls, cytochrome P4501A1 polymorphism, and postmenopausal breast cancer risk. Cancer Epidemiol Biomarkers Prev. Jan 1999;8(1):41-44.
138. Zhang Y, Wise JP, Holford TR, et al. Serum polychlorinated biphenyls, cytochrome P-450 1A1 polymorphisms, and risk of breast cancer in Connecticut women. Am J Epidemiol. Dec. 15 2004;160(12):1177-1183.
139. McElroy JA, Shafer MM, Trentham-Dietz A, Hampton JM, Newcomb PA. Cadmium exposure and breast cancer risk. J Natl Cancer Inst. Jun. 21, 2006;98(12):869-873.
140. Nie J, Beyea J, Bonner MR, et al. Exposure to traffic emissions throughout life and risk of breast cancer: the Western New York Exposures and Breast Cancer (WEB) study. Cancer Causes Control. Nov. 2007;18(9):947-955.
141. McElroy JA, Egan KM, Titus-Ernstoff L, et al. Occupational exposure to electromagnetic field and breast cancer risk in a large, population-based, case-control study in the United States. J Occup Environ Med. Mar. 2007;49(3):266-274.
142. Coogan PF, Clapp RW, Newcomb PA, et al. Occupational exposure to 60-Hertz magnetic fields and risk of breast cancer in women. Epidemiology. Sep. 1996;7(5):459-464.
143. Lie JA, Kjaerheim K. Cancer risk among female nurses: a literature review. Eur J Cancer Prev. Dec. 2003;12(6):517-526.
144. Pollan M, Gustavsson P. High-risk occupations for breast cancer in the Swedish female working population. Am J Public Health. Jun. 1999;89(6):875-881.
145. Pukkala E, Auvinen A, Wahlberg G. Incidence of cancer among Finnish airline cabin attendants, 1967-92. Bmj. Sep. 9, 1995;311(7006):649-652.
146. Reynolds P, Cone J, Layefsky M, Goldberg DE, Hurley S. Cancer incidence in California flight attendants (United States). Cancer Causes Control. May 2002;13(4):317-324.
147. Ray RM, Gao DL, Li W, et al. Occupational exposures and breast cancer among women textile workers in Shanghai. Epidemiology. May 2007;18(3):383-392.
148. Coogan PF, Newcomb PA, Clapp RW, Trentham-Dietz A, Baron JA, Longnecker MP. Physical activity in usual occupation and risk of breast cancer (United States). Cancer Causes Control. Jul. 1997;8(4):626-631.
149. Davis S, Mirick DK, Stevens RG. Night shift work, light at night, and risk of breast cancer. J Natl Cancer Inst. Oct. 17, 2001;93(20):1557-1562.
150. Schernhammer ES, Kroenke CH, Laden F, Hankinson SE. Night work and risk of breast cancer. Epidemiology. Jan 2006;17(1):108-111.
151. Straif K, Bann R, Grosse Y, et al. Carcinogenicity of shift-work, painting, and fire-fighting. Lancet Oncol. 2007;8:1065-1066.
152. IARC. Ionizing Radiation, Part I, X-and Gamma-Radiation and Neutrons. Vol 75 Pt 1. 26 May-2 June 1999. Lyon, France: WHO/IARC; 2000.
153. IARC. Ionizing Radiation, Part 2. Some Internally Deposited Radionuclides. Vol 78. Lyon, France: IARC; 2001.
154. Boice JD Jr. Radiation and breast carcinogenesis. Med Pediatr Oncol. May 2001;36(5):508-513.
155. Mattsson A, Ruden BI, Hall P, Wilking N, Rutqvist LE. Radiation-induced breast cancer: long-term follow-up of radiation therapy for benign breast disease. J Natl Cancer Inst. Oct. 20, 1993;85(20):1679-1685.
156. Morin Doody M, Lonstein JE, Stovall M, Hacker DG, Luckyanov N, Land CE. Breast cancer mortality after diagnostic radiography: findings from the U. S. Scoliosis Cohort Study. Spine. Aug. 15, 2000;25(16):2052-2063.
157. Travis LB, Hill DA, Dores GM et al Breast cancer following radiotherapy and chemotherapy among young women treated for Hodgkin's disease. JAMA. 2003;290:465-475.
158. Modan B, Chetrit A, Alfandary E, Katz L. Increased risk of breast cancer after low-dose irradiation. Lancet. Mar. 25, 1989;1(8639):629-631.
159. Land CE, Tokunaga M, Koyama K, et al. Incidence of female breast cancer among atomic bomb survivors, Hiroshima and Nagasaki, 1950-1990. Radiat Res. Dec. 2003;160(6):707-717.
160. Seidman H, Stellman SD, Mushinski MH. A different perspective on breast cancer risk factors: some implications of the nonattributable risk. CA Cancer J Clin. Sep-Oct. 1982;32(5):301-313.
161. Bruzzi P, Green SB, Byar DP, Brinton LA, Schairer C. Estimating the population attributable risk for multiple risk factors using case-control data. Am J Epidemiol. Nov. 1985;122(5):904-914.
162. Madigan MP, Ziegler RG, Benichou J, Byrne C, Hoover RN. Proportion of breast cancer cases in the United States explained by well-established risk factors. J Natl Cancer Inst. Nov. 15, 1995;87(22):1681-1685.
163. Mezzetti M, La Vecchia C, Decarli A, Boyle P, Talamini R, Franceschi S. Population attributable risk for breast cancer: diet, nutrition, and physical exercise. J Natl Cancer Inst. Mar. 4, 1998;90(5):389-394.
164. Sprague BL, Trentham-Dietz A, Egan KM, Titus-Ernstoff L, Hampton JM, Newcomb PA. Proportion of invasive breast cancer attributable to risk factors modifiable after menopause. Am J Epidemiol. Jun. 13, 2008;168(4):404-411.